These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 28839056)
1. The organoid architect. Sinha G Science; 2017 Aug; 357(6353):746-749. PubMed ID: 28839056 [No Abstract] [Full Text] [Related]
2. A combination therapy for cystic fibrosis. Brodsky JL; Frizzell RA Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363 [TBL] [Abstract][Full Text] [Related]
3. PharmGKB summary: very important pharmacogene information for CFTR. McDonagh EM; Clancy JP; Altman RB; Klein TE Pharmacogenet Genomics; 2015 Mar; 25(3):149-56. PubMed ID: 25514096 [No Abstract] [Full Text] [Related]
4. Aquagenic wrinkling of the palms in a patient with cystic fibrosis. Grasemann H; Ratjen F; Solomon M N Engl J Med; 2013 Dec; 369(24):2362-3. PubMed ID: 24328486 [No Abstract] [Full Text] [Related]
5. False dawn for cystic fibrosis disease modifiers? Holmes D Nat Rev Drug Discov; 2014 Oct; 13(10):713-4. PubMed ID: 25270946 [No Abstract] [Full Text] [Related]
6. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy? van Koningsbruggen-Rietschel S; Naehrlich L Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480 [No Abstract] [Full Text] [Related]
7. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis. Dekkers JF; Berkers G; Kruisselbrink E; Vonk A; de Jonge HR; Janssens HM; Bronsveld I; van de Graaf EA; Nieuwenhuis EE; Houwen RH; Vleggaar FP; Escher JC; de Rijke YB; Majoor CJ; Heijerman HG; de Winter-de Groot KM; Clevers H; van der Ent CK; Beekman JM Sci Transl Med; 2016 Jun; 8(344):344ra84. PubMed ID: 27334259 [TBL] [Abstract][Full Text] [Related]
8. Breathing easier with combinations. Azvolinsky A Nat Biotechnol; 2015 Nov; 33(11):1128-30. PubMed ID: 26544137 [No Abstract] [Full Text] [Related]
9. CFTR potentiators: not an open and shut case. Clancy JP Sci Transl Med; 2014 Jul; 6(246):246fs27. PubMed ID: 25101884 [TBL] [Abstract][Full Text] [Related]
10. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction. Brewington JJ; McPhail GL; Clancy JP Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802 [TBL] [Abstract][Full Text] [Related]
11. Ivacaftor (Kalydeco) for cystic fibrosis. Med Lett Drugs Ther; 2012 Apr; 54(1388):29-30. PubMed ID: 22499233 [No Abstract] [Full Text] [Related]
12. 50 years ago in The Journal of Pediatrics: The use of N-acetylcysteine in the treatment of cystic fibrosis. Cantu-Gonzalez G J Pediatr; 2014 Oct; 165(4):721. PubMed ID: 25256050 [No Abstract] [Full Text] [Related]
14. A bioassay using intestinal organoids to measure CFTR modulators in human plasma. Dekkers R; Vijftigschild LA; Vonk AM; Kruisselbrink E; de Winter-de Groot KM; Janssens HM; van der Ent CK; Beekman JM J Cyst Fibros; 2015 Mar; 14(2):178-81. PubMed ID: 25467948 [TBL] [Abstract][Full Text] [Related]
15. Targeting the basic defect in cystic fibrosis. Welsh MJ N Engl J Med; 2010 Nov; 363(21):2056-7. PubMed ID: 21083391 [No Abstract] [Full Text] [Related]
16. Excitement mounts for first disease-modifying cystic fibrosis drugs. Opar A Nat Rev Drug Discov; 2011 Jul; 10(7):479-80. PubMed ID: 21720393 [No Abstract] [Full Text] [Related]